The World Health Organisation has given the go-ahead for emergency use of Moderna's COVID-19 vaccine.
The mRNA vaccine from the US manufacturer joins vaccines from AstraZeneca, Pfizer-BioNTech and Johnson & Johnson in receiving the WHO's emergency use listing.
Similar approvals for China's Sinopharm and Sinovac vaccines are expected in the coming days and weeks, WHO has said.
The greenlight for Moderna's vaccine, announced late Friday, took many months because of delays that WHO faced in getting data from the manufacturer.
Many countries without their own advanced medical regulatory and assessment offices rely on the WHO listing to decide whether to use vaccines. UN children's agency UNICEF also uses the listing to deploy vaccines in an emergency like the pandemic.
The announcement, however, wasn't likely to have an immediate impact on supplies of Moderna's vaccine for the developing world. The company struck supply agreements with many rich countries, which will have already received millions of doses.
In a statement Friday, CEO Stephane Bancel said Moderna was actively participating in discussions with multilateral organisations, such as COVAX, to help protect populations around the world.
He was referring to a UN-backed programme to ship COVID-19 vaccines to many low- and middle-income countries, based on need.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)